NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Secondary nonalcoholic fatty liver disease (NAFLD) defines those complex pathophysiological and clinical consequences that ensue when the liver becomes an ectopic site of lipid storage owing to reasons other than its mutual association with the metabolic syndrome. Disorders affecting gonadal hormones, thyroid hormones, or growth hormones (GH) may cause secondary forms of NAFLD, which exhibit specific pathophysiologic features and, in theory, the possibility to receive an effective treatment. Here, we critically discuss epidemiological and pathophysiological features, as well as principles of diagnosis and management of some common endocrine diseases, such as polycystic ovary syndrome (PCOS), hypothyroidism, hypogonadism, and GH deficiency. Collectively, these forms of NAFLD secondary to specific endocrine derangements may be envisaged as a naturally occurring disease model of NAFLD in humans. Improved understanding of such endocrine secondary forms of NAFLD promises to disclose novel clinical associations and innovative therapeutic approaches, which may potentially be applied also to selected cases of primary NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121 · cited 1×
“In 1935, Stein and Leventhal, two American gynecologists, were first in describing PCOS by reporting a series of patients exhibiting the syndromic tetrad of ovarian cysts, chronic anovulation, obesity, and hirsutism [23].”
BackgroundGlobal perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Chaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Yildiz, B. O., Bozdag, G., Yapici, Z., Esinler, I., & Yarali, H. (2012) · Human Reproduction · doi:10.1093/humrep/des232 · Cited by 704
Insulin-Like Growth Factor (IGF) System in Liver Diseases
Adamek, A., & Kasprzak, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051308 · Cited by 284 · cited 2×
“Based on the finding that untreated AGHD patients exhibit a metabolic syndrome-like phenotype, which is strongly and bi-directionally associated with NAFLD, a potential association between GHD and NAFLD was suggested [134].”
BackgroundMelatonin in type 2 diabetes mellitus and obesity
Karamitri, A., & Jockers, R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0130-1 · Cited by 268
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00010 · Cited by 257
Sex hormones and their receptors regulate liver energy homeostasis
Shen, M., & Shi, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/294278 · Cited by 239 · cited 2×
“However, some common pathogenic mechanisms may be identified, which closely mirror the biological end-result of the defective hormones (Table 4) [108].”
BackgroundThyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study
Bano, A., Chaker, L., Plompen, E. P. C., Hofman, A., Dehghan, A., Franco, O. H., Janssen, H. L. A., Murad, S. D., & Peeters, R. P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1300 · Cited by 209 · cited 2×
“[70] A population-based, prospective cohort study (the Rotterdam study): 9419 Dutch euthyroid individuals Subclinical hypothyroidism was defined as serum TSH levels >4.”
BackgroundKumarendran, B., O’Reilly, M. W., Manolopoulos, K. N., Toulis, K. A., Gokhale, K. M., Sitch, A. J., Wijeyaratne, C. N., Coomarasamy, A., Arlt, W., & Nirantharakumar, K. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002542 · Cited by 206
The role of growth hormone and insulin-like growth factor-I in the liver
Takahashi, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071447 · Cited by 193
Kim, D., Kim, W., Joo, S. K., Bae, J. M., Kim, J. H., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.014 · Cited by 191 · cited 1×
“[75] Cross-sectional study: 425 South Koreans with biopsy-proven NAFLD Subclinical hypothyroidism was defined as serum TSH >4.”
BackgroundEffects of growth hormone on glucose metabolism and insulin resistance in human
Kim, S.-H., & Park, M.-J. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.3.145 · Cited by 181 · cited 4×
“GHD in adults (AGHD), in most cases due to either hypothalamic and pituitary lesions or their treatment, leads to detrimental metabolic consequences typically involved in NAFLD pathogenesis, such as visceral obesity, dyslipidemia, and insulin resistance, carrying an inherently increased prevalence of metabolic syndrom…”
BackgroundInfluentialEffect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
Prevalence of hypothyroidism in nonalcoholic fatty liver disease
Pagadala, M. R., Zein, C. O., Dasarathy, S., Yerian, L. M., Lopez, R., & McCullough, A. J. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-2006-2 · Cited by 178 · cited 1×
“[57] Case-control study: 246 US patients with biopsy-proven NAFLD and 430 age-, sex-, race-, and BMI-matched controls Hypothyroidism was defined by the self-reported use of levothyroxine Biopsy Alcohol use Hypothyroidism was independently associated with an increased risk of NAFLD”
MethodIGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Nishizawa, H., Iguchi, G., Fukuoka, H., Takahashi, M., Suda, K., Bando, H., Matsumoto, R., Yoshida, K., Odake, Y., Ogawa, W., et al. (2016) · Scientific Reports · doi:10.1038/srep34605 · Cited by 164 · cited 2×
“Instead, IGF-1 seems to affect the biology of hepatic stellate cells by inducing their senescence and inactivation, thereby limiting hepatic fibrogenesis [161].”
BackgroundEstrogen replacement in Turner syndrome: literature review and practical considerations
Klein, K. O., Rosenfield, R. L., Santen, R. J., Gawlik, A. M., Backeljauw, P. F., Gravholt, C. H., Sas, T. C. J., & Mauras, N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02183 · Cited by 151 · cited 1×
“Hypogonadism in women is treated with estrogen replacement through a variety of strategies spanning from treatment with low-dose transdermal E2, oral micronized E2, or per the intramuscular route; after progestin is added, a pill containing both an estrogen and a progestin may be preferable owing to the ease of its us…”
BackgroundHyperandrogenic origins of polycystic ovary syndrome-Implications for Pathophysiology and Therapy
Abbott, D. H., Dumesic, D. A., & Levine, J. E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1576522 · Cited by 131
Lonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
Self-citationHormone replacement therapy may improve hepatic function in women with Turner's syndrome
Elsheikh, M., Hodgson, H. J. F., Wass, J. A. H., & Conway, G. S. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01321.x · Cited by 109 · cited 1×
“[93] Retrospective analysis of serum liver enzymes in 80 women with TS, followed by a prospective study in 20 women with TS following 3 months on-and-off HRT GGT, AST, and ALP 44% of women with TS had RLE.”
MethodBruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00475 · Cited by 108
Arturi, F., Succurro, E., Procopio, C., Pedace, E., Mannino, G. C., Lugarà, M., Procopio, T., Andreozzi, F., Sciacqua, A., Hribal, M. L., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1227 · Cited by 103
Haider, A., Gooren, L. J. G., Padungtod, P., & Saad, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1202774 · Cited by 83 · cited 1×
“[88] A cohort of 117 hypogonadic men (34–69 years), who were treated with HRT (testosterone undecanoate for 1 year) ALT, AST, and CRP HRT was associated with a significant reduction in adiposity measures, lipid profile, and rate of individuals who met the criteria of the MetS.”
MethodBarbonetti, A., Caterina Vassallo, M. R., Cotugno, M., Felzani, G., Francavilla, S., & Francavilla, F. (2016) · The Journal of Spinal Cord Medicine · doi:10.1179/2045772314y.0000000288 · Cited by 75
Koulouri, O., Ostberg, J., & Conway, G. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03203.x · Cited by 71
Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment
de la Garza, R. G., Morales-Garza, L. A., Martin-Estal, I., & Castilla-Cortazar, I. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2761w · Cited by 55
Du, Q., Wang, Y.-J., Yang, S., Wu, B., Han, P., & Zhao, Y.-Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.681636 · Cited by 53 · cited 1×
“Preliminary evidence also suggests some benefit of pioglitazone in the treatment of women with PCOS [20,44], as well as the use of either liraglutide or other glucagon-like peptide-1 receptor agonists for decreasing intra-hepatic fat content and visceral adipose tissue among women with PCOS who exhibit overweight/obes…”
Background
Cited by
Sex and gender: modifiers of health, disease, and medicine
Mauvais-Jarvis, F., Bairey Merz, N., Barnes, P. J., Brinton, R. D., Carrero, J.-J., DeMeo, D. L., De Vries, G. J., Epperson, C. N., Govindan, R., Klein, S. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31561-0 · Cited by 2,001
Self-citationTargher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00020-0 · Cited by 586
Self-citationComplications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553
Self-citationHutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Lonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
“Men with Klinefelter Syndrome (XXY) are associated with an increased prevalence of insulin resistance, T2D [56] and NAFLD [1].”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Lonardo, A., Mantovani, A., Lugari, S., & Targher, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-06-11
- Volume
- 20
- Issue
- 11
- Pages
- 2841
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2951348577
- Cited by
- 120
- References
- 31
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.